The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the Midwest CEPAC process, and Find out how topics are selected.
Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the Midwest CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the Midwest CEPAC. For more information about past and other upcoming meetings, see the box to the right.
University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121
Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in Caucasian populations. CF is a progressive disease that affects many organ systems, but most of its morbidity and mortality are associated with its impact on the respiratory system.
Interventions of Interest:
- Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals)
- Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals)
- Ivacaftor (Kalydeco®, Vertex Pharmaceuticals)